Table 1:

Patient and Treatment Characteristics^*

Patient	Age at CAR T/ Gender	Diagnosis	Donor Type	Graft source	Conditioning regimen with alloHCT	GVHD prophylaxis/ GVHD at CAR T	Interval/ lines of therapy between alloHCT and CAR T (days)	Donor chimerism at the time of mononuclear apheresis	CRS/ Neurotoxicity	Response at 1 month	B cell recovery	Status at last follow up
1	38/ M	T cell rich DLBCL	10/10 MUD	Peripheral blood	Flu, Cy, Thio, 400cGy TBI	Tacrolimus, Methotrexate/ none	1,914/ one	T cell chimerism 100% donor	Grade 2/ Grade 2	PR	Not achieved until last follow up	Dead (106 days post CAR T) from disease
2	55/ M	Non-GCB DLBCL	MMRD (haploidentical from cousin)	Bone marrow	Flu Mel, Thiotepa	Post-transplant Cy, Tacrolimus, Mycophenolate/ chronic GVHD stable on ibrutinib	269/ two	Whole blood 100% donor (T cell subset chimerism not available)	None/ none	CR	B cell recovery at 9 months	Alive with CR (270 days post CAR T)
3	56/ M	Non-GCB DLBCL	10/10 MUD	Peripheral blood	Thio, Bu, Cy, Rituximab	Tacrolimus, Alemtuzumab/ none	291/ three	T cell chimerism 18% donor	None/ none	POD	Not achieved until last follow up	Dead (77 days post CAR T) from disease
4	66/ F	Double hit DLBCL	9/10 MMUD	Peripheral blood	Flu, Mel	Tacrolimus, Methotrexate/ none	694/ none	Bone marrow (unsorted) 100% donor	Grade 2/ none	CR	Not available	Alive with CR (112 days post CAR T)

^*All patients received Flu/ Cy lymphodepletion and axicabtagene ciloleucel (2 x 10⁸ cells)

alloHCT, Allogeneic hematopoietic cell transplantation; Bu, Busulfan; CAR-T, Chimeric Antigen Receptor T cell therapy; CR, complete response; CRS, Cytokine release syndrome; Cy, Cyclophosphamide; DLBCL, Diffuse large B cell lymphoma; F, Female; Flu, Fludarabine; GCB, Germinal Center B cell like; GVHD, Graft versus host disease; M, Male; Mel, Melphalan; MMRD, Mismatched related donor; MMUD, Mismatched unrelated donor; MUD, Matched unrelated donor; POD, Progression of disease; PR, Partial response; TBI, Total Body Irradiation; Thio, thiotepa